China Biologic Products Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From China Biologic Products Holdings, Inc.
The official verdict is in for sintilimab and the results are not surprising. But some view the setback for "Made In China" innovation as a chance to reflect and move forward.
From Biogen to Takeda, multinationals have been cutting prices in China in a bid to seize the emerging market for rare disease treatments, as Beijing strives to expand market access.
Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.
Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.
- Large Molecule
- Other Names / Subsidiaries
- CBPO Holdings Limited
- CBPO Group Limited
- Guiyang Dalin Biologic Technologies Co., Ltd.
- Guizhou Taibang Biological Products Co. Ltd.
- Shandong Taibang Biological Products Co., Ltd.
- Tianxinfu Medical Appliance Co., Ltd.